An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020-Reference-Cited by-同舟云学术

An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020

Published:2021-12 Issue: Volume: Page:
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Wang Shuhang,Yang Qiuyan,Deng Lan,Lei Qi,Yang Yuqi,Ma Peiwen,Men Yuxin,Yung Bryant C.,Lee Robert J.,Zhang Mengzi,Li Ning

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference48 articles.

1. European Medicines Agency (EMA). European public assessment reports. https://www.ema.europa.eu/sites/default/files/Medicines_output_european_public_assessment_reports.xlsx [accessed May 26, 2021].

2. FDA Office of Pharmaceutical Quality. Center for Drug Evaluation and Research 2020 Annual Report. https://www.fda.gov/media/145830/download. Published 2021 [accessed May 26, 2021].

3. Informa: Pharma intelligence. https://pharmaintelligence.informa.com [accessed May 26, 2021].

4. Clinical development success rates for investigational drugs;Hay;Nat Biotechnol,2014

5. Uzu S. Latest trend of pharmaceutical and medical device regulation in Japan. https://www.pmda.go.jp/files/000236925.pdf. Published October 15, 2020 [accessed May 26, 2021].

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fabrication of Bacterial Cellulose/Chitosan-MIL-100(Fe) Composite for Adsorptive Removal of Dacarbazine;International Journal of Biological Macromolecules;2024-02

2. Critical insights into the evolving drug‐approval process in China;Cancer;2024-01-02

3. Trends in oncology drug lags in Japan from 2001 to 2020: A cross‐sectional study;Clinical and Translational Science;2023-10-17

4. Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations;JNCI: Journal of the National Cancer Institute;2023-10-12

5. The role of Real-World Data and evidence in oncology medicines approved in EU in 2018–2019;Journal of Cancer Policy;2023-06